Antifungal chemotherapy.
When the decision to treat a fungal infection is made, there are several antifungal agents available for use. AmB remains the first-line drug in the treatment of most systemic fungal infections. Miconazole should be used to treat patients who cannot tolerate AmB or who are infected with AmB-resistant organisms. Ketoconazole has a distinct advantage in that it is a relatively nontoxic oral agent and may prove very effective in treating non-life-threatening chronic fungal infections. Clinical experience with miconazole and ketoconazole is too limited at present to recommend them as first-line therapeutic agents, except in a limited number of clinical situations. 5-FC should only be used in combination with AmB to treat yeast infections.
D000666:Amphotericin B / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D000935:Antifungal Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations; D005437:Flucytosine / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000378:metabolism / Q000627:therapeutic use; D007223:Infant; D009181:Mycoses / Q000188:drug therapy*; D011193:Potassium Iodide / Q000008:administration & dosage / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D000935:Antifungal Agents; D004338:Drug Combinations; D007093:Imidazoles; D011193:Potassium Iodide; D000666:Amphotericin B; D005437:Flucytosine